Understanding Heart Failure

Heart failure (HF) is a condition where the heart cannot pump blood efficiently. This is because the heart, a muscle that squeezes and relaxes with each heartbeat, becomes too weak or too stiff to work properly.1

In a healthy heart, the left ventricle and left atrium relax to fill with blood from the lungs. Once filled, the left ventricle pumps the blood to the body.

In patients with HF, the pressure inside the left atrium increases. The high pressure may be due to a weakened heart muscle that doesn’t effectively pump blood out to the body.

Or, the high pressure may be due to a stiff heart muscle that can’t easily fill with blood.

In either case, the high pressure in the left side of the heart causes blood to back up into the lungs, causing shortness of breath and fatigue. These common symptoms of worsening heart failure often result in hospitalizations.

What is the Corvia® Atrial Shunt?

The Corvia Atrial Shunt is a cardiac implant designed to reduce heart failure symptoms by decreasing pressure in the left side of the heart and the lungs. It is implanted via a minimally invasive procedure. During this procedure, an interventional cardiologist or electrophysiologist inserts a catheter (small tube) in a vein near the groin to access the heart. This catheter is then used to create a very small passage in the heart wall between the right and left atria where the shunt is placed. The newly created passage allows blood to flow from the high pressure left atrium to the lower pressure right atrium. As a result, the pressure in the left side of the heart and the lungs decreases, and heart failure symptoms are reduced.

Learn how the Corvia Atrial Shunt is placed
by watching this animation

The Corvia Atrial Shunt is an investigational device and is currently only available through clinical studies.
Read more about the REDUCE LAP-HF IV study and see if you may qualify.

Clinical Experience

The Corvia Atrial Shunt is the most widely studied interatrial shunt for heart failure. It has been implanted in nearly 500 patients worldwide, and more than 40 patients have had the shunt for over 5 years.2

REDUCE LAP-HF IV is the fifth in a series of REDUCE LAP-HF trials studying the Corvia Atrial Shunt. While we continue to learn more about its performance through ongoing studies, evidence collected to date demonstrates both a short-term and longer-term benefit in patients who receive the device:


After 1 year, 71% of patients had fewer HF symptoms3


After 3 years, 75% of patients reported an improved quality of life4


After 3 years, 69% of patients had no hospitalizations for heart failure4

~500 Patients

have received the Corvia Atrial Shunt

18 Countries

in which the Corvia Atrial shunt has been studied

100+ Hospitals

with Corvia Atrial Shunt study experience

7+ Years

post-implant for the first Corvia Atrial Shunt patients

Benefits and Risks


As with any medical procedure, the Corvia Atrial Shunt has potential benefits and risks. It is important that you talk with your doctor to understand the benefits and risks associated with this device.

Potential benefits for people implanted with the Corvia Atrial Shunt as part of this study include the following:

  • Reduction in shortness of breath
  • Reduction in the number of hospitalizations and/or hospital days for HF symptoms
  • Reduction in the number of emergency room visits
  • Reduction in heart failure medications
  • Improved exercise tolerance
  • Improved quality of life
  • Improved life expectancy


The risks associated with the implant procedure are similar to the risks of other catheter based cardiac procedures in which devices are permanently implanted in the atrium or in the heart wall between the two atria. Because these procedures are common, these potential risks are uncommon; interventional cardiologists, electrophysiologists and their staff are well trained to reduce the likelihood and manage procedural risks.

Potential but uncommon long-term device risks include movement or fracture after placement, a blood clot that forms on or near the device and travels through the heart causing a blockage of a blood vessel (embolization, infarction with potential stroke), perforation or erosion of the heart wall, headache, chest pain, heart rhythm changes, or gradual implant occlusion and return of HF symptoms. The device is intended as a permanent implant, and does not need to be removed unless there is a medical reason to do so.